KT&G Life Sciences
2002
FOUNDED
M&A
STATUS
21-30
EMPLOYEES
M&A
LATEST DEAL TYPE
2
FINANCING ROUNDS
Description
Developer of medicines and drugs. The company is researching drugs for treating Cancer, Obesity, Type-2 Diabetes, Liver Disease, MELAS Syndrome, Dry Eye Syndrome, Atopic Dermatitis and other metabolic diseases.
Website
Formerly Known As
Mazence
Ownership Status
Acquired/Merged
(Operating Subsidiary)
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Parent Company
Primary Office
- B-1004-6 Digital Empire Building 16
- Deogyang-daero 1556 beon-gil Yeongtong-gu
- Suwon-si, Gyeonggi-do 443-702
- South Korea
+82 000-000-0000
KT&G Life Sciences Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore KT&G Life Sciences‘s full profile, request access.
Request full access to PitchBookKT&G Life Sciences Former Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore KT&G Life Sciences‘s full profile, request access.
Request full access to PitchBook